Click here to view with images.
To ensure delivery to your inbox, please add to your address book.
Intelligent Investment
SF Bay Area Venture Capital Funding
Predominantly Tech in San Francisco and Life Sciences in San Mateo
March 23, 2022
Source: CB Insights, CBRE Research, March 2022.

U.S. venture capital funding hit record levels in 2021, reaching $276 billion according to CBRE Research analysis of CB Insights data. The San Francisco Bay Area accounted for 38% or $103 billion of the nation's funding—a significantly higher share than other major metros, including New York (17%), Boston (11%) and Los Angeles (6%).

Companies based in the City of San Francisco received over half of the Bay Area’s venture capital funding in 2021. San Francisco's funding levels increased from $20 billion in 2020 to $52 billion in 2021. Silicon Valley (Santa Clara County) had 554 venture capital deals that totaled $23 billion in 2021 for an average placement of $41 million, $2 million higher than San Francisco’s average.

By industry sector, tech companies had the highest funding level in the Bay Area, accounting for 89% of total 2021 funding. Tech companies received 97% of the $52 billion funded in San Francisco and 92% of the $23 billion funded in Silicon Valley. The life sciences industry had total funding of $9 billion across the Bay Area in 2021, 14% higher than in 2020 and 61% higher than in 2019. Over 60% of the Bay Area’s life sciences funding was placed in companies headquartered in San Mateo County.

For more information, please contact:
Colin Yasukochi
Executive Director
CBRE Tech Insights Center

Sarah Bonnarens
Associate Director
CBRE Research


You may also unsubscribe by calling toll-free +1 877 CBRE 330 (+1 877 227 3330).

Please consider the environment before printing this email.

CBRE respects your privacy. A copy of our Privacy Policy is available online. For California Residents, our California Privacy Notice is available here. If you have questions or concerns about our compliance with this policy, please email or write to Attn: Marketing Department, Privacy Administrator, CBRE, 200 Park Ave. 19-22 Floors, New York, NY 10166.

Address: 415 Mission Street, 46th Floor Suite 700, San Francisco CA 94105

© Copyright 2023. All rights reserved. This report has been prepared in good faith, based on CBRE's current anecdotal and evidence based views of the commercial real estate market. Although CBRE believes its views reflect market conditions on the date of this presentation, they are subject to significant uncertainties and contingencies, many of which are beyond CBRE's control. In addition, many of CBRE's views are opinion and/or projections based on CBRE's subjective analyses of current market circumstances. Other firms may have different opinions, projections and analyses, and actual market conditions in the future may cause CBRE's current views to later be incorrect. CBRE has no obligation to update its views herein if its opinions, projections, analyses or market circumstances later change.

Nothing in this report should be construed as an indicator of the future performance of CBRE's securities or of the performance of any other company's securities. You should not purchase or sell securities-of CBRE or any other company-based on the views herein. CBRE disclaims all liability for securities purchased or sold based on information herein, and by viewing this report, you waive all claims against CBRE as well as against CBRE's affiliates, officers, directors, employees, agents, advisers and representatives arising out of the accuracy, completeness, adequacy or your use of the information herein.

CBRE and the CBRE logo are service marks of CBRE, Inc. All other marks displayed on this document are the property of their respective owners, and the use of such logos does not imply any affiliation with or endorsement of CBRE.

Photos herein are the property of their respective owners. Use of these images without the express written consent of the owner is prohibited.

All of CBRE's COVID-19 related materials have been developed with information from the World Health Organization, the Centers for Disease Control & Prevention (and similar global organizations), public health experts, industrial hygienists, and global subject matter experts across CBRE and our strategic suppliers. Our materials may not be suitable for application to all facilities or situations.

Ultimately, occupiers and landlords must make and implement their own reopening decisions for their individual stakeholders and facilities. CBRE's guidance is intended to help facilitate those discussions and expedite the implementation of those decisions once made by the client. We make no representations or warranties regarding the accuracy or completeness of these materials. CBRE cannot ensure safety and disclaims all liability arising from use of these materials.